...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Est. Cash Position

Thanks RVXOT.

In my 10 or 11 years with RVX and ZEN since 2013 I've been a bit nervous about the finances on occassions but Don always pulled it off.

Now it seems different. The scientific assets have never shown more value & promise than they do now. 

And yet now, more than ever, Don seems to be floundering.

There are Canadian based biotech financing companies with international affiliates and deep pockets and yet Zenith and RVX have to turn to financing from China? I have no idea what is going on. Perhaps Don is in complete control.

But I'm also wondering if Don becomes too desparate what Ori's game plan is.

There is no doubt in my mind that both companies will succeed but I wonder who will be in control when financial success is achieved and will there be a reward for retail shareholders?

Toinv

Share
New Message
Please login to post a reply